Managers / Q4 2022 · view latest →
Sivik Global Healthcare LLC
CIK 0001596452 · 133 TACONIC RD, GREENWICH, CT, 06831 · 203-769-8600
Reported Value
$213M
Q4 2022
Positions
39
Filings on Record
30
2019–present window
Filed
Feb 8, 2023
original filing
Summary
Sivik Global Healthcare LLC reported $213M in U.S.-listed holdings across 39 positions for Q4 2022.
Its largest position, XBI, represents 6.8% of the portfolio.
Compared with Q3 2022, the fund opened 5 new positions and exited 7.
Portfolio Metrics
Turnover
+12.3%
vs prior filed quarter
Top-10 Concentration
+40.4%
share of reported value
Largest Position
+6.8%
Spdr S P Biotech Etf
New / Exited
5 / 7
positions this quarter
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Common Stock · 89.1% · $189M
- ETP · 6.8% · $15M
- ADR · 4.1% · $9M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| VRTXVertex Pharmaceuticals Inc | NEW | +15.0K | 15.0K | +$4M | $4M |
| ICLRICON PLC | NEW | +15.0K | 15.0K | +$3M | $3M |
| GMEDGlobus Medical Inc | NEW | +37.7K | 37.7K | +$3M | $3M |
| MRNAModerna Inc | NEW | +13.0K | 13.0K | +$2M | $2M |
| BNTXBioNTech SE | NEW | +13.0K | 13.0K | +$2M | $2M |
| XBISPDR S&P Biotech ETF | ADDED | +163.7K | 175.0K | +$14M | $15M |
| CNCCentene Corp | SOLD OUT | −50.0K | 0 | −$4M | $0 |
| MDTMedtronic PLC | SOLD OUT | −30.0K | 0 | −$2M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2022
39 positions
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | XBISPDR S&P Biotech ETFhistory → | Cash Securities | 6.83% | $15M | 175.0K |
| 2 | BSXBoston Scientific Corphistory → | Cash Securities | 4.03% | $9M | 185.0K |
| 3 | SYKStryker Corphistory → | Cash Securities | 4.02% | $9M | 35.0K |
| 4 | HCAHCA Healthcare Inchistory → | Cash Securities | 3.95% | $8M | 35.0K |
| 5 | THCTenet Healthcare Corphistory → | Cash Securities | 3.79% | $8M | 165.0K |
| 6 | ISRGIntuitive Surgical Inchistory → | Cash Securities | 3.74% | $8M | 30.0K |
| 7 | UHSUniversal Health Services Inchistory → | Cash Securities | 3.64% | $8M | 55.0K |
| 8 | ZBHZimmer Biomet Holdings Inchistory → | Cash Securities | 3.60% | $8M | 60.0K |
| 9 | BAXBaxter International Inchistory → | Cash Securities | 3.60% | $8M | 150.0K |
| 10 | NVONovo Nordisk A/Shistory → | Cash Securities | 3.18% | $7M | 50.0K |
| 11 | HUMHumana Inchistory → | Cash Securities | 3.13% | $7M | 13.0K |
| 12 | CICigna Corphistory → | Cash Securities | 3.12% | $7M | 20.0K |
| 13 | LLYEli Lilly & Cohistory → | Cash Securities | 3.01% | $6M | 17.5K |
| 14 | BMRNBioMarin Pharmaceutical Inchistory → | Cash Securities | 2.92% | $6M | 60.0K |
| 15 | TMOThermo Fisher Scientific Inchistory → | Cash Securities | 2.85% | $6M | 11.0K |
| 16 | AAgilent Technologies Inchistory → | Cash Securities | 2.81% | $6M | 40.0K |
| 17 | ACHCAcadia Healthcare Co Inchistory → | Cash Securities | 2.71% | $6M | 70.0K |
| 18 | MCKMcKesson Corphistory → | Cash Securities | 2.65% | $6M | 15.0K |
| 19 | CAHCardinal Health Inchistory → | Cash Securities | 2.53% | $5M | 70.0K |
| 20 | DHRDanaher Corphistory → | Cash Securities | 2.50% | $5M | 20.0K |
| 21 | WATWaters Corphistory → | Cash Securities | 2.42% | $5M | 15.0K |
| 22 | EHCEncompass Health Corphistory → | Cash Securities | 2.39% | $5M | 85.0K |
| 23 | CORAmerisourceBergen Corphistory → | Cash Securities | 2.34% | $5M | 30.0K |
| 24 | ABTAbbott Laboratorieshistory → | Cash Securities | 2.32% | $5M | 45.0K |
| 25 | SGRYSurgery Partners Inchistory → | Cash Securities | 2.16% | $5M | 165.0K |
| 26 | VRTXVertex Pharmaceuticals Inchistory → | Cash Securities | 2.04% | $4M | 15.0K |
| 27 | UNHUnitedHealth Group Inchistory → | Cash Securities | 1.99% | $4M | 8.0K |
| 28 | ELVElevance Health Inchistory → | Cash Securities | 1.93% | $4M | 8.0K |
| 29 | OPCHOption Care Health Inchistory → | Cash Securities | 1.84% | $4M | 130.0K |
| 30 | IQVIQVIA Holdings Inchistory → | Cash Securities | 1.45% | $3M | 15.0K |
| 31 | ICLRICON PLChistory → | Cash Securities | 1.37% | $3M | 15.0K |
| 32 | RVTYPerkinElmer Inchistory → | Cash Securities | 1.32% | $3M | 20.0K |
| 33 | GMEDGlobus Medical Inchistory → | Cash Securities | 1.32% | $3M | 37.7K |
| 34 | BIIBBiogen Inchistory → | Cash Securities | 1.30% | $3M | 10.0K |
| 35 | JNJJohnson & Johnsonhistory → | Cash Securities | 1.25% | $3M | 15.0K |
| 36 | S24Select Medical Holdings Corphistory → | Cash Securities | 1.17% | $2M | 100.0K |
| 37 | MRNAModerna Inchistory → | Cash Securities | 1.10% | $2M | 13.0K |
| 38 | BNTXBioNTech SE | Cash Securities | 0.92% | $2M | 13.0K |
| 39 | Seagen Inc | Cash Securities | 0.79% | $2M | 13.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $132M | 34 | Apr 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $345M | 49 | Jan 21, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $344M | 44 | Oct 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $368M | 46 | Jul 25, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $185M | 31 | Apr 22, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $190M | 38 | Jan 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $236M | 35 | Nov 6, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $278M | 38 | Jul 29, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $427M | 47 | May 1, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $239M | 39 | Feb 5, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $198M | 33 | Nov 7, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $428M | 43 | Aug 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $233M | 40 | May 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $213M | 39 | Feb 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $180M | 41 | Nov 4, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $176M | 38 | Aug 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $242M | 49 | May 9, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $233M | 45 | Feb 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $419M | 43 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $512M | 49 | Aug 10, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $274M | 47 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $245M | 38 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $232M | 38 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $302M | 52 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $253M | 40 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $269M | 50 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $198M | 45 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $414M | 62 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $271M | 61 | May 8, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $186M | 48 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.